Inflammatory bowel diseases and the general practitioner's role in a region of central Italy

Clinical and Experimental Gastroenterology

Volumn 3, Issue 1, 2010, Pages 27-31

  Sossai, Paolo ^a,b   Filippetti, Fabio ^c   Muselmani, Ali Ahmad ^d   Catalini, Giambattista ^d  

^a Enrico Mattei Hospital   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

^c Epidemiological Unit   (Italy)

^d General Hospital   (Italy)

Author keywords

Crohn's disease; General practitioner; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; CALGRANULIN; PROBIOTIC AGENT;

ADULT; ARTICLE; COLONOSCOPY; CONTINUING EDUCATION; COST CONTROL; CROHN DISEASE; ENTERITIS; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HOSPITALIZATION; HUMAN; INVASIVE PROCEDURE; ITALY; MALE; PATIENT COUNSELING; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; RELAPSE; ULCERATIVE COLITIS;

EID: 77953413382     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/ceg.s9334     Document Type: Article

References (22)

1. Garcia Rodriguez LA, Gozalez-Perez A, Johansson S, et al. Risks factors for inflammatory bowel disease in the general population. Aliment Pharmacol Ther. 2005;22:309-315.
2. Ekbom A. The changing faces of Crohn's disease and ulcerative colitis. In: Targan SR, Shanahan F, Karp LC, editors. Inflammatory Bowel Disease. From Bench to Bedside. New York, NY: Springer Science; 2003. p. 5-20.
3. Ranzi T, Bodini P, Zambelli A, et al. Epidemiological aspects of inflammatory bowel disease in a north Italian population: A 4-year prospective study. Eur J Gastroenterol Hepatol. 1996;8:657-661
4. Howarth GF, Robinson MHE, Jenkins D, et al. High prevalence of undetected ulcerative colitis: Data fom the Nottingham Fecal Occult Blood Screening Trial. Am J Gastroenterol. 2002;97:690-694.
5. http://www.amiciitalia.net/index.php?option=com_docman&task=doc-download&gid=131.
6. Rubin GP, Hungin APS, Kelly PJ, Ling J. Inflammatory bowel disease: Epidemiology and management in an English general practice population. Aliment Pharmacol Ther. 2000;14:1553-1559.
7. Numans ME. Chronic abdominal pain. In: Jones R, Britten N, Culpepper L, Gass D, Grol R, Mant D Silagy, editors. Oxford Textbook of Primary Medical Care. Oxford: Oxford University Press; 2005. p. 742-746.
8. Sands BE. Crohn's disease. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Philadelphia, PA: Saunders Elsevier; 2006. p. 2459-2498.
9. Rolland N, Grandbastien B, Merle V, et al. Coùt de la première prise en charge des maladies inflammatoires chronique de l'intestin. Gastroenterol Clin Biol. 1999;23:483-488. French.
10. Stone MA, Mayberry JF, Baker R. Prevalence and management of inflammatory bowel disease: A cross-sectional study from central England. Eur J Gastroenterol Hepatol. 2003;15:1275-1280.
11. Konikoff MR, Denson LA. Role of the calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:524-534.
12. D'Incà R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol. 2008;103:2007-2014.
13. Williams JG, Cheung WY, Russel IT, et al. Open access follow up for inflammatory bowel disease: Pragmatic randomised trial and cost effectiveness study. Br Med J. 2000;320:544-548.
14. Casellas F, Fontanet G, Borruel N, et al. The opinion of patients with inflammatory bowel disease on healthcare received. Rev Esp Enferm Dig. 2004;96:174-184.
15. Drossmann DA, Ringel Y. Psychosocial factors in ulcerative colitis and Crohn's disease. In: Sartor RB, Sandborn WJ, editors. Kirsner's Inflammatory Bowel Diseases. Edinburgh: Saunders; 2004. p. 340-356.
16. Martinato M, Ferrante M, Burattin B, et al. Understanding of disease in patients with a recent diagnosis of inflammatory bowel disease. Journal of Crohn's and Colitis Suppl. 2008;2:45.
17. de Boer AG, Sprangers MA, Barrtelsman JF, et al. Predictors of health care utilization in patients with inflammatory bowel disease: A longitudinal study. Eur J Gastroenterol Hepatol 1998;10:783-789.
18. D'Incà R, Bertomoro P, Mazzocco K, Vettorato MG, Rumiati R, Sturniolo GC. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2008;27:166-172.
19. Cunliffe RN, Scott BB. Review article: Monitoring for drug side-effects in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16: 647-662.
20. Sossai P, Cappellato MG, Stefani S. Can a drug-induced hypersensitivity reaction be dose-dependent? A case with mesalamine. Mt Sinai J Med. 2001;68:389-395.
21. Stark R, Konig HH, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics. 2006;24:797-814.
22. Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007;56:830-837.